Standout Papers

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With ... 2014 2026 2018 2022 473
  1. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib (2017)
    Cameron J. Turtle, Kevin A. Hay et al. Journal of Clinical Oncology
  2. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia (2014)
    Jennifer R. Brown, John C. Byrd et al. Blood

Citation Impact

29 from Science/Nature 93 standout
Sub-graph 1 of 16

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
2 intermediate papers

Works of Daniel Li being referenced

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management
2016
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
2014 Standout

Author Peers

Author Oncology Genetics Immunology PFM Last Decade Papers Cites
Daniel Li 969 859 497 643 62 2.3k
Stephen L. Wood 1 48 1.7k
Peter Callan 6 3 9 21 34 908
Fernand Dagher 8 10 1 26 31 402
Timofei Istomin 17 207
T. Grotker 3 271

All Works

Loading papers...

Rankless by CCL
2026